Clinical trial
AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients…
NCT00219557 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00219557 |
|---|---|
| Title | AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer |
| Official title | A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTION |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Neoplasms |
| Intervention type | Drug |
| Interventions | Gemcitabine, AG-013736 |
| Enrollment | 111 |
| Start date | Jul 5, 2005 |
| Primary completion | Mar 14, 2008 |
| Completion | Mar 14, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | May 14, 2019 |
| Countries | Belgium, Canada, France, Germany, Italy, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: